Balyasny Asset Management
MYGN icon

Balyasny Asset Management’s Myriad Genetics MYGN Stock Holding History

Balyasny Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Buy
+36,860
New +$167K ﹤0.01% 2812
2026
Q1 		– Sell
-16,155
Closed -$99.4K – 3295
2025
Q4 		$99.4K Sell
16,155
-128,790
-89% -$934K ﹤0.01% 2963
2025
Q3 		$1.05M Buy
+144,945
New +$861K ﹤0.01% 2095
2025
Q2 		– Sell
-862,787
Closed -$7.65M – 3165
2025
Q1 		$7.65M Buy
862,787
+779,405
+935% +$9.36M 0.01% 1056
2024
Q4 		$1.14M Buy
+83,382
New +$1.54M ﹤0.01% 1889
2023
Q4 		– Sell
-290,808
Closed -$4.66M – 2754
2023
Q3 		$4.66M Sell
290,808
-1,155,937
-80% -$22M 0.01% 1126
2023
Q2 		$33.5M Sell
1,446,745
-142,232
-9% -$3.1M 0.07% 364
2023
Q1 		$36.9M Buy
+1,588,977
New +$32.3M 0.09% 309
2022
Q4 		– Sell
-26,245
Closed -$501K – 3069
2022
Q3 		$501K Sell
26,245
-8,755
-25% -$201K ﹤0.01% 2039
2022
Q2 		$636K Sell
35,000
-286,067
-89% -$5.94M ﹤0.01% 1910
2022
Q1 		$8.09M Buy
+321,067
New +$8.22M 0.03% 771
2021
Q4 		– Sell
-221,193
Closed -$7.14M – 2485
2021
Q3 		$7.14M Buy
+221,193
New +$7.35M 0.03% 701
2021
Q2 		– Sell
-213,566
Closed -$6.5M – 2213
2021
Q1 		$6.5M Sell
213,566
-318,529
-60% -$9.04M 0.03% 606
2020
Q4 		$10.5M Buy
532,095
+335,573
+171% +$5.42M 0.06% 421
2020
Q3 		$2.56M Buy
196,522
+49,941
+34% +$632K 0.02% 777
2020
Q2 		$1.66M Buy
+146,581
New +$2.08M 0.01% 748
2019
Q1 		– Sell
-32,610
Closed -$948K – 1551
2018
Q4 		$948K Sell
32,610
-9,150
-22% -$329K 0.01% 916
2018
Q3 		$1.92M Buy
+41,760
New +$1.86M 0.01% 993
2018
Q2 		– Sell
-25,355
Closed -$749K – 2025
2018
Q1 		$749K Buy
25,355
+3,937
+18% +$133K ﹤0.01% 1320
2017
Q4 		$736K Buy
+21,418
New +$723K ﹤0.01% 1421
2017
Q1 		– Sell
-12,886
Closed -$215K – 1724
2016
Q4 		$215K Buy
+12,886
New +$233K ﹤0.01% 1273

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Balyasny Asset Management's MYGN Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Myriad Genetics (MYGN) in Q2 2026: 36,860 shares worth $210K. The stake represents ﹤0.01% of the portfolio and ranks #2812 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in MYGN as recently as Q4 2025.

Balyasny Asset Management first reported a position in MYGN in Q4 2016 and has held it in 21 quarters since. The position peaked at $36.9M in Q1 2023. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Balyasny Asset Management held 36,860 shares of Myriad Genetics worth $210K as of Q2 2026.
  • Myriad Genetics was a new Balyasny Asset Management position in Q2 2026.
  • Myriad Genetics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2812 holding.
  • Balyasny Asset Management first reported a position in Myriad Genetics in Q4 2016 and has held it in 21 quarters since.
  • Balyasny Asset Management's Myriad Genetics position peaked at $36.9M in Q1 2023.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.